Testicular Germ Cell Tumor CRISPR Models for Drug Discovery

Testicular germ cell tumors (TGCTs) are the most common malignancy in men aged 15-44 years, with an age-standardized incidence rate of approximately 6.7 per 100,000 in developed countries (WHO, 2022). The global incidence has been rising over the past decades. While the 5-year survival rate for localized disease exceeds 95% (NCI, SEER data), metastatic or cisplatin-resistant TGCTs have a significantly worse prognosis, with survival dropping to 50-70%. Key risk factors include cryptorchidism, family history, and testicular dysgenesis syndrome. TGCTs are classified into seminomas and non-seminomas (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma), each with distinct clinical behaviors and therapeutic responses.

TGCTs are an ideal model for studying germ cell biology, pluripotency, and chemotherapy resistance. They share molecular features with embryonic stem cells, including expression of pluripotency markers (OCT4, NANOG, SOX2). Public datasets from TCGA (TGCT cohort, n=150) and GEO provide extensive genomic, transcriptomic, and epigenomic data. Open questions include the mechanisms of cisplatin resistance, the role of the tumor microenvironment, and the development of targeted therapies for refractory disease. Gene-edited cell models are essential to dissect these mechanisms.

TGCT development is driven by aberrant germ cell development and acquisition of pluripotency. Key pathways include:

1. KIT/KITLG signaling: Activating mutations in KIT (receptor tyrosine kinase) or its ligand KITLG are early events, promoting survival and proliferation of primordial germ cells.

2. RAS/RAF/MEK/ERK pathway: Downstream of KIT, this pathway is frequently hyperactivated via mutations in KRAS, NRAS, or BRAF.

3. PI3K/AKT/mTOR pathway: PIK3CA mutations or PTEN loss lead to constitutive activation, supporting growth and resistance to apoptosis.

4. p53 pathway: TP53 mutations are rare in primary TGCTs but are enriched in cisplatin-resistant and metastatic tumors, highlighting its role in chemosensitivity.

Data from TCGA (2017) and COSMIC (v99).

Key signaling networks in TGCTs include:

• • MAPK/ERK pathway: Activated by KIT, KRAS, NRAS, and BRAF mutations. Promotes cell cycle progression and survival.
• • PI3K/AKT/mTOR pathway: Activated by PIK3CA mutations or PTEN loss. Drives protein synthesis, growth, and metabolism.
• • Wnt/β-catenin pathway: CTNNB1 mutations (exon 3) are found in 10-15% of TGCTs, leading to nuclear β-catenin accumulation and transcription of target genes (MYC, CCND1).
• • Pluripotency network: OCT4, NANOG, and SOX2 are overexpressed in embryonal carcinoma and seminoma, maintaining stemness and blocking differentiation.

Organoid models derived from patient tumors recapitulate the histology and heterogeneity of TGCTs, including seminoma and non-seminoma subtypes, and are useful for drug testing and personalized medicine.

• • Patient-derived xenografts (PDXs): Implantation of TGCT tissue into immunodeficient mice (e.g., NSG). Retain tumor heterogeneity and are used for preclinical drug evaluation.
• • Genetically engineered mouse models (GEMMs): Conditional activation of KIT D814V in germ cells leads to testicular tumors resembling human seminoma.
• • Induced models: Transgenic mice expressing SV40 T antigen under the germ cell-specific promoter develop TGCTs.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications in TGCT-relevant genes. Examples include:

• • TP53 knockout lines: Generated in NCCIT or 2102Ep cells to model cisplatin resistance.
• • KIT knock-in lines: Introduction of activating mutations (e.g., D816V) to study oncogenic signaling.
• • KRAS G12D knock-in lines: To investigate MAPK pathway dependency.
• • Reporter lines: OCT4-GFP or NANOG-luciferase for monitoring pluripotency.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools for functional studies, drug screening, and target validation.

Knockout and knock-in cell lines are used to validate the role of candidate genes in TGCT biology. For example:

• • TP53 knockout in NCCIT cells leads to increased resistance to cisplatin, confirming its role in chemosensitivity.
• • KIT D816V knock-in in 2102Ep cells enhances proliferation and activates MAPK signaling, demonstrating oncogenic potential.
• • PTEN knockout in GCT27 cells activates AKT signaling and promotes tumor growth in xenografts.

Isogenic pairs (e.g., TP53 wild-type vs. knockout) are used in high-throughput screens to identify drugs that selectively target resistant cells. For example:

• • Screening of a library of kinase inhibitors in KIT-mutant vs. wild-type isogenic lines identifies selective inhibitors.
• • Cisplatin-resistant models (TP53 knockout) are used to test combination therapies (e.g., MDM2 inhibitors + cisplatin).

CRISPR-based synthetic lethality screens in TGCT cell lines identify genes whose loss is lethal only in specific genetic backgrounds. For example:

• • A genome-wide CRISPR screen in TP53-null TGCT cells identified WEE1 as a synthetic lethal target, leading to the development of WEE1 inhibitors for resistant tumors.
• • Screens in KIT-mutant lines identified downstream effectors (e.g., MEK) as potential biomarkers of response.